Established in 2008, PharmAbcine Inc. is an antibody therapeutics biotech company located in Daejeon, South Korea. We are developing therapeutic antibodies for oncology, immuno-oncology and ophthalmology indications. We generate our antibody pipeline from our proprietary HuPhage library and innovative selection system.
Our lead asset olinvacimab is a tumor angiogenesis inhibitor with a best-in-class potential, and is currently in three clinical studies. Our potentially first-in-class preclinical assets are being prepared for clinical studies in 2022: PMC-309 (anti-VISTA mAb) and PMC-403 (anti-TIE2 mAb).
Our lead asset olinvacimab is a tumor angiogenesis inhibitor with a best-in-class potential, and is currently in three clinical studies. Our potentially first-in-class preclinical assets are being prepared for clinical studies in 2022: PMC-309 (anti-VISTA mAb) and PMC-403 (anti-TIE2 mAb).
Ticker:
208340
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
Olinvacimab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
